CRVS
Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (CRVS) Stock News
The latest CRVS headlines and market coverage — 1 recent story, updated throughout the day.
- The Motley Fool·
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Corvus Pharmaceuticals director David Scott Moore purchased 21,700 common shares for approximately $250,000 on June 11, 2026, marking his first investment in the company since joining as a director in October. Moore also received 15,000 stock options vesting in a year. The insider buy is viewed as a positive signal, though it should be considered alongside other investment factors.